March 26, 2010
Posted by on
Why Did the Duck Kill the Chicken? Well… a scientific explanation is RIG-I. Ducks are resistant to influenza viruses but may by asymptomatic carriers. One of the reasons for ducks’ resistance is because ducks express the RIG-I protein that senses the presence of the viruses. Chickens, however, do not appear to express RIG-I or a similar protein and have no method to detect the presence of viruses to illicit an immune response. This could have implications to the poultry industry who do not want to see their entire farm wiped out by a viral outbreak and may want to start breeding transgenic chickens expressing RIG-I. The discovery was led by Dr. Katharine Magor and her team at the University of Alberta and is published in the early edition of the Proceedings of the National Academy of Sciences.
Promoting Cancer Cell Growth: The YB-1 (Y-box binding protein-1) transcription factor is a known oncogene that is expressed in a significant percentage of breast cancers. In this study, scientists demonstrated that YB-1 induces the expression of CD44 and CD49f, which are associated with cancer stem cells and used as stem cell markers. Although they do not make a direct link to breast cancer stem cells, they suggest that it is this link that explains why YB-1 expressing cancers are resistant to drugs such as paclitaxel and are associated with disease recurrence and poor outcome. The principal investigator of the study was Dr. Sandra Dunn at the University of British Columbia. Details of the study were reported in Cancer Research.
Knock, knock… Let Me In: A transporter protein that is selectively expressed in blood cells can be manipulated to facilitate the entry of cancer drugs into the cell. This is extremely important for new treatment regimes against blood cancers such as AML and other leukemias. Researchers found that the Human Carnitine Transporter encoded by the SLC22A16 gene acts as a gateway and can mediate the uptake of the polyamine class of drugs such as the anti-cancer agent Bleomycin. Dr. Dindial Ramotar, Université de Montréal, first demonstrated this in yeast cells and now in human cells as reported in the Journal of Biological Chemistry.
Please, No More Radiation: A genetic mutation in the p53 gene in children with a rare type of brain cancer – choroid plexus carcinoma (CPC) – is a new marker indicating a poor response to radiation therapy. It is unfortunate that this signals a more aggressive disease, however, this finding would relieve the patient of having to suffer through the difficulties of radiation. The inherited p53 mutation is associated with a condition called Li-Fraumeni syndrome and is found in about 50% of CPC cases. Without the mutation, CPC patients treated by radiation have a good chance of recovery. The study, led by Dr. David Malkin at the Hospital for Sick Children, Toronto, is published in the advance online issue of the Journal of Clinical Oncology.
Mooooooooo: Scientists have finished sequencing the genome of two different types of cows – one beef and one dairy – using Life Technologies’ next generation SOLiD™ 3 System. It cost $130K and took only seven months to complete. In comparison, it cost $50M and four years, finishing in 2009, to sequence the first cow. The genomic information is important to the industry for making breeding decisions and to identify genetic markers of specific desirable traits. So that T-bone steak waiting for you to grill up this summer will be even juicier and tastier. The Bovine Genomics Program at the University of Alberta led by Dr. Stephen Moore performed the sequencing study.
November 26, 2009
Posted by on
Last week, Harvard Medical School held a conference entitled “Personalized Medicine: The Time is Now.” Is the time now? Looking around, it seems like personalized medicine has had a pretty good month:
PBMs Drive Demand
CVS Caremark, the country’s largest pharmacy services provider, partnered with Generation Health to expand pharmacogenomic testing for cancer, cardiovascular diseases, and HIV. According the GenomeWeb story, CVS Caremark joins Medco‘s 60 million people, meaning the top two PBMs in the U.S. are investing heavily in personalized medicine.
Though note that PBMs’ interest in personalized medicine isn’t wholly neutral, as this post at IVB by Michael McCaughan points out.
Three pairs of corporations found the economics sufficiently attractive to strike new partnership deals:
NCI Investment To Advance Research
Finally, helping ensure that there is sufficient research output to advance the field, the National Cancer Institute put out a program announcement entitled “Development, Application, and Evaluation of Prediction Models for Cancer Risk and Prognosis,” which NCI says will be “essential for tailoring therapy to appropriate groups of patients.”
Still, as the Washington Post notes in its article on the new “Ignite Institute” in Fairfax County: “[y]ou’d be right, of course, to be a bit skeptical,” citing decades of promise and so far few commercial successes in the region.
Given this month’s developments, our Magic 8-Ball says “Outlook good.” Stay tuned to see what develops, particularly as personalized medicine and comparative effectiveness grow in prominence at the same time.
September 14, 2009
Posted by on
The Monday Deal Review is back in full force this week following a Labo(u)r Day vacation last week and there’s plenty of news including more information on the MDS-Danaher transaction and plenty of other companies finding ways to raise money and keep the lights on. Keep reading after the jump…